RS54903B1 - Inhibitor fosfoinozitid 3 kinaze sa delom koji vezuje cink - Google Patents

Inhibitor fosfoinozitid 3 kinaze sa delom koji vezuje cink

Info

Publication number
RS54903B1
RS54903B1 RS20160457A RSP20160457A RS54903B1 RS 54903 B1 RS54903 B1 RS 54903B1 RS 20160457 A RS20160457 A RS 20160457A RS P20160457 A RSP20160457 A RS P20160457A RS 54903 B1 RS54903 B1 RS 54903B1
Authority
RS
Serbia
Prior art keywords
phosphoinositide
kinase inhibitor
binding moiety
zinc binding
zinc
Prior art date
Application number
RS20160457A
Other languages
English (en)
Inventor
Xiong Cai
Haixiao Zhai
Chengjung Lai
Changgeng Qian
Rudi Bao
Original Assignee
Curis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curis Inc filed Critical Curis Inc
Publication of RS54903B1 publication Critical patent/RS54903B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members

Abstract

Jedinjenje prema Formuli I:i njihove farmaceutski prihvatljive soli, gde R je vodonik ili acil grupa.Prijava sadrži još 14 patentnih zahteva.
RS20160457A 2011-04-01 2012-03-30 Inhibitor fosfoinozitid 3 kinaze sa delom koji vezuje cink RS54903B1 (sr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161470849P 2011-04-01 2011-04-01
US201161559489P 2011-11-14 2011-11-14
EP12764605.7A EP2694075B1 (en) 2011-04-01 2012-03-30 Phosphoinositide 3-kinase inhibitor with a zinc binding moiety
PCT/US2012/031361 WO2012135571A1 (en) 2011-04-01 2012-03-30 Phosphoinositide 3-kinase inhibitor with a zinc binding moiety

Publications (1)

Publication Number Publication Date
RS54903B1 true RS54903B1 (sr) 2016-10-31

Family

ID=46931927

Family Applications (2)

Application Number Title Priority Date Filing Date
RSP20190842 RS59219B1 (sr) 2011-04-01 2012-03-30 Inhibitor fosfoinozitid 3 kinaze sa delom koji vezuje cink
RS20160457A RS54903B1 (sr) 2011-04-01 2012-03-30 Inhibitor fosfoinozitid 3 kinaze sa delom koji vezuje cink

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RSP20190842 RS59219B1 (sr) 2011-04-01 2012-03-30 Inhibitor fosfoinozitid 3 kinaze sa delom koji vezuje cink

Country Status (30)

Country Link
US (7) US8710219B2 (sr)
EP (2) EP3111938B1 (sr)
JP (3) JP6242331B2 (sr)
KR (2) KR101902325B1 (sr)
CN (2) CN105461736B (sr)
AU (1) AU2012236367B2 (sr)
BR (1) BR112013025340B1 (sr)
CA (1) CA2830822C (sr)
CL (1) CL2013002823A1 (sr)
CY (2) CY1117785T1 (sr)
DK (2) DK2694075T3 (sr)
EA (1) EA022434B9 (sr)
ES (2) ES2577982T3 (sr)
HK (1) HK1194969A1 (sr)
HR (2) HRP20160545T1 (sr)
HU (2) HUE028910T2 (sr)
IL (2) IL228588A (sr)
LT (1) LT3111938T (sr)
ME (2) ME03523B (sr)
MX (1) MX340577B (sr)
PE (1) PE20141382A1 (sr)
PL (2) PL2694075T3 (sr)
PT (2) PT2694075T (sr)
RS (2) RS59219B1 (sr)
SG (2) SG10201602569RA (sr)
SI (2) SI2694075T1 (sr)
SM (1) SMT201600179B (sr)
TW (1) TWI571469B (sr)
WO (1) WO2012135571A1 (sr)
ZA (2) ZA201307082B (sr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2385832E (pt) * 2009-01-08 2015-11-02 Curis Inc Inibidores de fosfoinoritide 3-quinase com uma fração de ligação ao zinco
LT3111938T (lt) * 2011-04-01 2019-06-25 Curis, Inc. Fosfoinozitido 3-kinazės inhibitorius su cinko rišamąja dalimi
HUE033032T2 (hu) 2011-11-14 2017-11-28 Ignyta Inc Uracil-származékok mint AXL és c-MET kináz inhibitorok
CN104725301A (zh) * 2013-12-20 2015-06-24 北京蓝贝望生物医药科技股份有限公司 一种1,2-二氢吡啶-2-酮衍生物的制备方法
CN107849045B (zh) 2015-04-21 2019-12-24 贵州百灵企业集团制药股份有限公司 嘌呤基-n-羟基嘧啶甲酰胺衍生物及其制备方法和用途
AU2017301012B2 (en) * 2016-07-19 2020-07-09 National Institute Of Plant Genome Research Novel protein against fungal pathogens
EA201991069A1 (ru) * 2016-11-02 2019-10-31 Комбинированная терапия ингибитором фосфоинозитид-3-киназы и связывающим цинк агентом
AU2018360845B2 (en) * 2017-11-06 2024-05-02 Cold Spring Harbor Laboratory Method and compositions for forming a copper-containing complex and uses thereof
JP7467423B2 (ja) 2018-09-11 2024-04-15 キュリス，インコーポレイテッド 亜鉛結合部分を有するホスホイノシチド３－キナーゼ阻害剤との併用療法
WO2023212574A1 (en) * 2022-04-26 2023-11-02 Olivia Szu Hsieh Lee Nakaya Compositions and methods for modulating rhythmic activity of pacemaker cardiomyocytes

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4828991A (en) 1984-01-31 1989-05-09 Akzo N.V. Tumor specific monoclonal antibodies
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5502187A (en) 1992-04-03 1996-03-26 The Upjohn Company Pharmaceutically active bicyclic-heterocyclic amines
US5497763A (en) 1993-05-21 1996-03-12 Aradigm Corporation Disposable package for intrapulmonary delivery of aerosolized formulations
US5508269A (en) 1994-10-19 1996-04-16 Pathogenesis Corporation Aminoglycoside formulation for aerosolization
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US6083922A (en) 1996-04-02 2000-07-04 Pathogenesis, Corp. Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis
US5767068A (en) 1997-02-13 1998-06-16 Pathogenesis Corporation Pure biologically active colistin, its components and a colistin formulation for treatment of pulmonary infections
WO2001083456A1 (fr) 2000-04-27 2001-11-08 Yamanouchi Pharmaceutical Co., Ltd. Derives d'heteroaryle condenses
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
MXPA04007776A (es) 2002-03-13 2004-10-15 Janssen Pharmaceutica Nv Derivados de sulfonilamino como nuevos inhibidores de histona deacetilasa.
CN101450934B (zh) 2002-03-13 2012-10-10 詹森药业有限公司 用作组蛋白去乙酰酶抑制剂的磺酰基衍生物
OA12790A (en) 2002-03-13 2006-07-10 Janssen Pharmaceutica Nv New inhibitors of histone deacetylase.
ES2306858T3 (es) 2002-03-13 2008-11-16 Janssen Pharmaceutica Nv Derivados de carbonilamino como nuevos inhibidores de las histonadesacetilasas.
AU2003255845A1 (en) 2002-08-22 2004-03-11 Piramed Limited Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
US7300935B2 (en) 2003-01-29 2007-11-27 Takeda Pharmaceutical Company Thienopyrimidine compounds and use thereof
JP4993374B2 (ja) * 2004-04-05 2012-08-08 メルク エイチディーエーシー リサーチ エルエルシー ヒストン脱アセチル化酵素インヒビタープロドラッグ
WO2005117909A2 (en) 2004-04-23 2005-12-15 Exelixis, Inc. Kinase modulators and methods of use
US7557112B2 (en) 2004-10-08 2009-07-07 Astellas Pharma Inc. Aromatic-ring-fused pyrimidine derivative
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
EP2500063A1 (en) 2005-02-03 2012-09-19 TopoTarget UK Limited Combination therapy using HDAC inhibitors and melphalan for treating cancer
US8138198B2 (en) 2005-05-18 2012-03-20 Angibaud Patrick Rene Substituted aminopropenyl piperidine or morpholine derivatives as novel inhibitors of histone deacetylase
WO2007082880A1 (en) 2006-01-19 2007-07-26 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
DK1981871T3 (da) 2006-01-19 2012-02-13 Janssen Pharmaceutica Nv Heterocyclylalkylderivater som hidtil ukendte inhibitorer af histondeacetylase
WO2007082874A1 (en) 2006-01-19 2007-07-26 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
CL2007001167A1 (es) * 2006-04-26 2008-01-25 Genentech Inc Compuestos derivados de pirimidina condensada, inhibidores de p13-quinasa; procesos para preparar los compuestos; composicion farmaceutica que los comprende; uso de los compuestos en la preparacion de medicamentos; proceso para preparar la composicion farmaceutica; y kit que incluye a la composicionfarmaceutica.
US7846929B2 (en) 2006-04-26 2010-12-07 Genentech, Inc. Phosphoinositide 3-kinase inhibitor compounds and methods of use
CL2007001165A1 (es) 2006-04-26 2008-01-25 Hoffmann La Roche 2-(1h-indazol-4-il)-6-(4-metanosulfonil-piperazin-1-ilmetil)-4-morfolin-4-il-tieno[3,2-d]pirimidina; procedimiento de preparacion; composicion farmaceutica; proceso de preparacion de dicha composicion; kit farmaceutico; y uso para tratar enfermedades tales como cancer, desordenes inmunes y enfermedades cardiovasculares.
WO2007131364A1 (en) 2006-05-16 2007-11-22 Mcgill University Hybrid molecules having mixed vitamin d receptor agonism and histone deacetylase inhibitory properties
AU2007296740B2 (en) 2006-09-11 2012-09-27 Curis, Inc. Substituted 2-indolinone as PTK inhibitors containing a zinc binding moiety
WO2008033749A2 (en) 2006-09-11 2008-03-20 Curis, Inc. Quinazoline based egfr inhibitors containing a zinc binding moiety
US20080161320A1 (en) 2006-09-11 2008-07-03 Xiong Cai Fused bicyclic pyrimidines as ptk inhibitors containing a zinc binding moiety
SG174772A1 (en) 2006-09-11 2011-10-28 Curis Inc Multi-functional small molecules as anti-proliferative agents
US7547781B2 (en) 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
EP2061468A4 (en) 2006-09-11 2011-05-04 Curis Inc TYROSINE KINASE INHIBITORS CONTAINING ZINC BINDING CHARACTERISTIC GROUP
CL2007003108A1 (es) 2006-10-28 2008-07-18 Methylgene Inc Envivo Pharmace Compuestos derivados de n-hidroxiamida sustituida con heterociclos, inhibidores de histona desacetilasa; composicion farmaceutica que comprende a dichos compuestos; y uso para tratar una enfermedad del grupo que consiste en enfermedad de huntington,
KR101507182B1 (ko) * 2006-12-07 2015-03-30 제넨테크, 인크. 포스포이노시타이드 3-키나제 억제제 화합물 및 그의 사용 방법
KR101460816B1 (ko) 2006-12-07 2014-11-12 에프. 호프만-라 로슈 아게 포스포이노시타이드 3-키나제 억제제 화합물 및 그의 사용 방법
AU2008216327A1 (en) 2007-02-15 2008-08-21 Novartis Ag Combination of LBH589 with other therapeutic agents for treating cancer
CA2680398A1 (en) 2007-03-20 2008-09-25 Curis, Inc. Raf kinase inhibitors containing a zinc binding moiety
TW200922564A (en) 2007-09-10 2009-06-01 Curis Inc CDK inhibitors containing a zinc binding moiety
WO2009036057A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Antiproliferative agents containing a zinc binding moiety
TW200922590A (en) 2007-09-10 2009-06-01 Curis Inc VEGFR inhibitors containing a zinc binding moiety
WO2009036020A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Mek inhibitors containing a zinc binding moiety
WO2009036066A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Vegfr inhibitors containing a zinc binding moiety
PE20140100A1 (es) * 2007-09-12 2014-02-12 Genentech Inc Combinaciones de compuestos inhibidores de fosfoinositida 3-quinasa y agentes quimioterapeuticos
WO2009042646A1 (en) 2007-09-24 2009-04-02 Curis, Inc. Anti-proliferative agents
US8354528B2 (en) 2007-10-25 2013-01-15 Genentech, Inc. Process for making thienopyrimidine compounds
US20090149511A1 (en) 2007-10-30 2009-06-11 Syndax Pharmaceuticals, Inc. Administration of an Inhibitor of HDAC and an mTOR Inhibitor
WO2009086012A1 (en) 2007-12-20 2009-07-09 Curis, Inc. Aurora inhibitors containing a zinc binding moiety
US20110178070A1 (en) 2008-06-24 2011-07-21 Takeda Pharmaceutical Company Limited PI3K/mTOR INHIBITORS
WO2009155659A1 (en) 2008-06-27 2009-12-30 The University Of Queensland Combination therapy
US8196911B2 (en) 2008-10-27 2012-06-12 Honda Motor Co., Ltd. Adjustable rate subframe mount
PT2385832E (pt) 2009-01-08 2015-11-02 Curis Inc Inibidores de fosfoinoritide 3-quinase com uma fração de ligação ao zinco
WO2010089411A2 (en) 2009-02-09 2010-08-12 Universite De La Mediterranee Pd-1 antibodies and pd-l1 antibodies and uses thereof
JP5709766B2 (ja) 2009-03-12 2015-04-30 ジェネンテック， インコーポレイテッド 造血器腫瘍の治療のためのホスホイノシチド３キナーゼ阻害剤化合物と化学療法剤の併用
NZ599939A (en) 2009-10-12 2014-02-28 Hoffmann La Roche Combinations of a pi3k inhibitor and a mek inhibitor
JP2013525308A (ja) 2010-04-16 2013-06-20 キュリス，インコーポレイテッド Ｋ−ｒａｓ変異を有する癌の治療
LT3111938T (lt) * 2011-04-01 2019-06-25 Curis, Inc. Fosfoinozitido 3-kinazės inhibitorius su cinko rišamąja dalimi
US20130102595A1 (en) 2011-04-15 2013-04-25 Curis, Inc. Treatment of cancers having k-ras mutations
MY193562A (en) 2011-08-01 2022-10-19 Genentech Inc Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
PT3313443T (pt) 2015-06-25 2023-08-30 Immunomedics Inc Combinação de anticorpos anti-hla-dr ou anti-trop-2 com inibidores de microtúbulos, inibidores de parp, inibidores de bruton quinase ou inibidores de fosfoinositídeo 3-quinase melhora significativamente o resultado terapêutico no cancro
EA201991069A1 (ru) * 2016-11-02 2019-10-31 Комбинированная терапия ингибитором фосфоинозитид-3-киназы и связывающим цинк агентом

Also Published As

Publication number Publication date
TWI571469B (zh) 2017-02-21
CN105461736B (zh) 2018-06-12
CN105461736A (zh) 2016-04-06
KR101902325B1 (ko) 2018-09-28
SI3111938T1 (sl) 2019-08-30
IL228588A (en) 2016-11-30
DK3111938T3 (da) 2019-07-01
CN103582483B (zh) 2016-02-17
PE20141382A1 (es) 2014-11-04
BR112013025340B1 (pt) 2021-12-21
MX2013011132A (es) 2014-03-12
EA022434B9 (ru) 2016-02-29
BR112013025340A2 (pt) 2016-12-13
CA2830822C (en) 2018-10-02
CL2013002823A1 (es) 2014-04-11
HRP20160545T1 (hr) 2016-06-17
EP2694075A4 (en) 2014-10-01
IL248597B (en) 2018-04-30
SG193563A1 (en) 2013-11-29
NZ705039A (en) 2016-03-31
JP2014509653A (ja) 2014-04-21
ES2577982T3 (es) 2016-07-19
JP2018052987A (ja) 2018-04-05
EA201301114A1 (ru) 2014-04-30
CY1121825T1 (el) 2020-07-31
MX340577B (es) 2016-07-13
NZ615586A (en) 2015-02-27
AU2012236367A1 (en) 2013-04-18
HUE028910T2 (en) 2017-01-30
HUE045041T2 (hu) 2019-12-30
AU2012236367B2 (en) 2014-10-09
HRP20191091T1 (hr) 2019-09-20
ZA201406167B (en) 2015-03-25
CA2830822A1 (en) 2012-10-04
ZA201307082B (en) 2015-04-29
EP2694075B1 (en) 2016-04-27
US20200215039A1 (en) 2020-07-09
EP2694075A1 (en) 2014-02-12
SI2694075T1 (sl) 2016-07-29
KR20180108848A (ko) 2018-10-04
TW201247678A (en) 2012-12-01
JP6275784B2 (ja) 2018-02-07
US20170304279A1 (en) 2017-10-26
US20220168284A1 (en) 2022-06-02
US10543197B2 (en) 2020-01-28
ES2733128T3 (es) 2019-11-27
PL3111938T3 (pl) 2019-09-30
US9249156B2 (en) 2016-02-02
PL2694075T3 (pl) 2016-09-30
US11135205B2 (en) 2021-10-05
SMT201600179B (it) 2016-08-31
ME02451B (me) 2016-09-20
US20140243330A1 (en) 2014-08-28
US20160185796A1 (en) 2016-06-30
JP2016188255A (ja) 2016-11-04
EP3111938A1 (en) 2017-01-04
IL248597A0 (en) 2016-12-29
US8710219B2 (en) 2014-04-29
LT3111938T (lt) 2019-06-25
CN103582483A (zh) 2014-02-12
US20130090335A1 (en) 2013-04-11
PT3111938T (pt) 2019-07-10
US20190091211A1 (en) 2019-03-28
EA022434B1 (ru) 2015-12-30
DK2694075T3 (en) 2016-08-01
SG10201602569RA (en) 2016-05-30
JP6242331B2 (ja) 2017-12-06
RS59219B1 (sr) 2019-10-31
ME03523B (me) 2020-04-20
US10111864B2 (en) 2018-10-30
KR20140023333A (ko) 2014-02-26
EP3111938B1 (en) 2019-05-08
WO2012135571A1 (en) 2012-10-04
PT2694075T (pt) 2016-07-11
HK1194969A1 (zh) 2014-10-31
IL228588A0 (en) 2013-12-31
US11654136B2 (en) 2023-05-23
CY1117785T1 (el) 2017-05-17
US9657032B2 (en) 2017-05-23

Similar Documents

Publication Publication Date Title
RS54903B1 (sr) Inhibitor fosfoinozitid 3 kinaze sa delom koji vezuje cink
RS54730B1 (sr) Inhibitori beta sekretaze
RS54386B1 (sr) Antiviralna jedinjenja
RS54207B1 (sr) Kondenzovani imidazolilimidazoli kao antiviralna jedinjenja
RS54526B1 (sr) Upotreba derivata pirazolospiroketona kao inhibitora acetil-coa karboksilaze
RS53301B (sr) Jednjenja tioacetata, kompozicije i postupci korišćenja
RS53503B1 (sr) Amorfna i kristalna forma genz 112638 hemitartarata kao inhibitor glikozilkeramid sintaze
EA201591503A1 (ru) Производные нафтиридина, полезные в качестве антагонистов альфа-v-бета-6 интегрина
RS54873B1 (sr) Policiklična-karbamoilpiridonska jedinjenja i njihova farmaceutska upotreba
RS54704B1 (sr) Supstituisani 5-fluor-1h-pirazolopiridini i njihova primena
RS54123B1 (sr) Terapeutska kombinacija koja sadrži dolutegravir, abacavir i lamivudine
UA113643C2 (xx) N-цикліламіди як нематоциди
RS54485B1 (sr) C7-fluoro supstituisana tetraciklinska jedinjenja
RS52716B (sr) Derivati hidrobenzamida kao inhibitori proteina toplotnog šoka hsp90
BR112012026950A2 (pt) composto, e, uso de um composto
RS54261B1 (sr) Upotreba sgc stimulatora, sgc aktivatora, pojedinačno i u kombinaciji sa pde5 inhibitorima za tretman sistemske skleroze (ssc)
CO6640320A2 (es) Composición de control de fitoenfermedades y metodo de control de fitoenfermedades
CR11518A (es) Compuestos de carbamoilo como inhibidores de dgat1 190
MY184978A (en) Pyridin-2-amides useful as cb2 agonists
WO2012096887A3 (en) Compositions comprising enzyme-cleavable oxycodone prodrug
IN2015DN01035A (sr)
RS53711B1 (sr) Sredstva za lečenje poremećaja koji uključuju modulaciju rijanodinskih receptora
RS54135B1 (sr) Jedinjenje kao inhibitor puteva prenosa notch signalizacije
UY33750A (es) ?Compuestos insecticidas aromáticos derivados de bisamida, procesos e intermediarios para prepararlos y composiciones que los usan.?
MX2016007861A (es) Compuestos de ácido dimetilbenzoico.